Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Acadian Asset Management LLC

Acadian Asset Management LLC decreased its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 65.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,230 shares of the company’s stock after selling 107,338 shares during the quarter. Acadian Asset Management LLC owned approximately 0.08% of Kiniksa Pharmaceuticals worth $1,067,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of KNSA. Essex Investment Management Co. LLC raised its position in Kiniksa Pharmaceuticals by 0.5% in the first quarter. Essex Investment Management Co. LLC now owns 172,740 shares of the company’s stock valued at $3,408,000 after purchasing an additional 850 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Kiniksa Pharmaceuticals by 5.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,935 shares of the company’s stock valued at $413,000 after buying an additional 1,153 shares during the period. SG Americas Securities LLC lifted its position in Kiniksa Pharmaceuticals by 8.1% in the first quarter. SG Americas Securities LLC now owns 19,160 shares of the company’s stock valued at $378,000 after buying an additional 1,435 shares during the last quarter. QRG Capital Management Inc. boosted its stake in Kiniksa Pharmaceuticals by 11.7% during the fourth quarter. QRG Capital Management Inc. now owns 16,010 shares of the company’s stock worth $281,000 after buying an additional 1,679 shares during the period. Finally, Linden Thomas Advisory Services LLC increased its position in shares of Kiniksa Pharmaceuticals by 1.7% during the second quarter. Linden Thomas Advisory Services LLC now owns 118,302 shares of the company’s stock valued at $2,209,000 after acquiring an additional 1,921 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on KNSA. Wedbush upped their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. Jefferies Financial Group began coverage on Kiniksa Pharmaceuticals in a research note on Friday. They set a “buy” rating and a $40.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $33.60.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, CEO Sanj K. Patel sold 136,124 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $25.65, for a total transaction of $3,491,580.60. Following the completion of the transaction, the chief executive officer now directly owns 63,012 shares of the company’s stock, valued at $1,616,257.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the sale, the insider now directly owns 52,038 shares in the company, valued at $1,359,232.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Sanj K. Patel sold 136,124 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $25.65, for a total value of $3,491,580.60. Following the transaction, the chief executive officer now directly owns 63,012 shares of the company’s stock, valued at $1,616,257.80. The disclosure for this sale can be found here. Insiders have sold 260,564 shares of company stock valued at $6,727,929 in the last quarter. Corporate insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock opened at $25.16 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $14.12 and a fifty-two week high of $27.92. The company has a 50 day moving average price of $24.72 and a 200 day moving average price of $21.08. The stock has a market capitalization of $1.78 billion, a P/E ratio of 228.73 and a beta of 0.33.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The business had revenue of $108.30 million during the quarter, compared to the consensus estimate of $90.60 million. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. The company’s quarterly revenue was up 51.5% compared to the same quarter last year. On average, research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.31 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.